-+ 0.00%
-+ 0.00%
-+ 0.00%

Plus Therapeutics Issues Business Update; REYOBIQ Phase 2 Data Readouts Expected In Q3 And Q4 2026

Benzinga·01/22/2026 12:49:23
Listen to the news

Plus Therapeutics, Inc. (NASDAQ:PSTV) (the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today provides a business update and highlights REYOBIQ clinical progress and CNSide US commercialization.

Overview of anticipated company milestones for 2026:

REYOBIQ clinical program:

  • Define optimal dose/interval for REYOBIQ in the ReSPECT-LM Phase 2 trial; anticipate reporting data in Q3 2026
  • Completing enrollment in the ReSPECT-GBM Phase 2 trial for glioblastoma and conduct an end of phase meeting with the FDA to align on pivotal trial design, with data expected in Q4 2026
  • Complete commercial manufacturing scale up for REYOBIQ
  • Begin enrollment in the ReSPECT-PBC pediatric brain cancer Phase 1 trial

CNSide commercial roll out:

  • Obtain a total of 150 million US lives covered under multiple commercial payor agreements
  • Obtain Medicare and Medicaid coverage  
  • Achieve a commercial order rate in excess of 1,250 tests per year
  • Launch portfolio of additional CSF tumor characterization tests that expand the CNSide testing platform